Efficacy of 13-valent polysaccharide conjugate vaccine (PCV13) against Pneumococcal Pneumonia in Adults

http://www.nejm.org/doi/full/10.1056/NEJMoa1408544

CONCLUSIONS

Among older adults, PCV13 was effective in preventing vaccine-type pneumococcal, bacteremic, and nonbacteremic community-acquired pneumonia and vaccine-type invasive pneumococcal disease but not in preventing community-acquired pneumonia from any cause. 

Uso de la vacuna antineumocócica en adultos

http://jama.jamanetwork.com/article.aspx?articleid=2110955

Major recommendations

• Pneumococcal vaccine–naive adults aged 65 years or older (or adults ≥65 years whose pneumococcal vaccine history is unknown) should receive 1 dose of 13-valent pneumococcal conjugate vaccine (PCV13) followed by a dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) 6 to 12 months later (minimum duration between PCV13 and PPSV23, 8 weeks).
• Adults aged 65 years or older who have previously received 1 or more doses of PPSV23 should receive 1 dose of PCV13 1 year or longer after the most recent PPSV23 dose.
• In adults who received PPSV23 before age 65 years, PCV13 should be given after age 65 years (and ≥1 year after the PPSV23 was given). PPSV23 should then be repeated 6 to 12 months later (and ≥5 years since the initial PPSV23 injection).

Efecto de la vacuna antineumocócica 13-valente sobre la enfermedad neumocócica invasiva en niños y adultos de USA

http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(14)71081-3/abstract

PCV13 reduced invasive pneumococcal disease across all age groups when used routinely in children in the USA. These findings provide reassurance that, similar to PCV7, PCVs with additional serotypes can also prevent transmission to unvaccinated populations.

Documento de consenso SEPAR-ALAT sobre vacunación antineumocócica en fumadores

https://www.alatorax.org/tabaquismo/biblioteca-tabaquismo/guias-tabaquismo/documento-de-consenso-separ-alat-sobre-vacunacion-antineumococica-en-fumadores

Streptococcus pneumoniae es causante de diversos cuadros clínicos: neumonía adquirida en la comunidad, sinusitis, otitis media, etc. Sin duda, la forma clínica más grave ocasionada por este germen es la enfermedad neumocócica invasiva. Se sabe que determinados factores, entre los que destaca el consumo de tabaco, y el padecimiento de enfermedades subyacentes concomitantes aumentan el riesgo de padecer estos procesos. Este artículo muestra un documento de consenso sobre vacunación antineumocócica en fumadores que ha sido realizado por un grupo de expertos en tabaquismo de la Sociedad Española de Neumología y Cirugía Torácica y de la Asociación Latinoamericana del Tórax.